ドライパウダー吸入器（DPI）の世界市場 - 2025～2033年

世界のドライパウダー吸入器市場は2024年に10億2,000万米ドルに達し、2033年には15億6,000万米ドルに達すると予測され、予測期間2025～2033年のCAGRは5.1%で成長すると予測されています。

ドライパウダー吸入器（DPI）は、粉末薬剤を肺に直接投与する医療機器です。一般に、喘息や慢性閉塞性肺疾患（COPD）などの呼吸器疾患の治療に使用されます。ドライパウダー吸入器は、患者がマウスピースから深く力強く吸入したときにのみ薬剤が放出されるようにする呼吸作動メカニズムによって区別されます。薬剤を投与するために推進剤を利用する定量吸入器（MDI）とは異なり、DPIは患者の吸入を利用して、粉末薬剤を肺の狭い気道に到達できるエアロゾル形態に分散させます。

ドライパウダー吸入器に対する需要の増加は、予測期間にわたって市場を牽引する要因です。例えば、呼吸器疾患の有病率の増加は、慢性呼吸器疾患の治療と管理において重要な役割を果たすため、ドライパウダー吸入器の需要を増加させます。例えば、米国喘息・アレルギー財団によると、米国では約2,800万人が喘息に苦しんでいます。これは約12人に1人の割合に相当します。米国では18歳以上の喘息患者数は2,300万人にのぼります。喘息は男性よりも女性に多いです。女性成人の約11.0％が喘息に罹患しており、男性成人の6.8％が喘息に罹患しています。喘息は若者の主要な慢性疾患です。現在、18歳未満の約490万人の子供が喘息を患っています。

市場力学：

促進要因と阻害要因

ドライパウダー吸入器の需要増加

ドライパウダー吸入器に対する需要の増加は、世界のドライパウダー吸入器市場の成長における重要な要因になると予想されます。呼吸器疾患の症例数の増加、従来の吸入器よりも薬剤デリバリーが容易であること、技術の進歩、研究資金の増加、意識の高まりなどが、ドライパウダー吸入器の需要を増加させ、市場を牽引しています。

COPD、喘息、副鼻腔炎のような慢性呼吸器疾患が世界的に流行するにつれ、気管支炎、COPD、喘息のような慢性呼吸器疾患の管理とコントロールに重要な役割を果たすため、ドライパウダー吸入器の需要が増加します。例えば、保健福祉省によると、世界では20人に1人が慢性呼吸器疾患（CRD）を患っています。CRDによる死亡率が最も高いのは東アジアと南アジアです。また、社会人口統計指数（SDI）が低中位および低位の国では、年齢標準化したCRD死亡率が最も高くなりました。慢性呼吸器疾患（CRD）に関する新たな知見によると、CRDは世界第3位の死因であり、世界中で約400万人が死亡しています。このうち約60％（約2億6,200万人）が喘息と診断され、最も一般的なCRDとなっています。1990年以降、CRDの新規症例数は49.0％増加していますが、これは主に人口増加によるものです。一方、年齢標準化罹患率は5.3％減少しています。

従来の吸入器に対するドライパウダー吸入器のドラッグデリバリーの容易さとユーザーフレンドリーな性質が、需要を増大させています。典型的な吸入装置に対するDPIの主な利点の一つは、肺に直接薬剤を送達する能力であり、推進剤や液体を必要としません。この特性は、患者のコンプライアンスを向上させるだけでなく、環境への影響も軽減します。DPIは使いやすく、持ち運びが可能であるため、慢性呼吸器疾患の継続的な治療が必要な患者に適した選択肢となります。DPIの使いやすさと有効性は、ヘルスケア専門家と患者の両方から受け入れられる原動力になると予測されます。

さらに、DPIの設計と製剤における技術的進歩が市場拡大の原動力となっています。湿気への暴露を低減するカプセル型デバイスのような技術革新は、信頼性と性能を向上させ、患者の満足度とアドヒアランスを高めます。使用状況をモニターするセンサーなど、スマート技術を吸入器に組み込むことで、治療成績と患者の参加を向上させる新たな展望が生まれます。こうした進歩は、既存の患者のニーズを満たすだけでなく、以前は吸入療法を採用したがらなかったような新規ユーザーをも惹きつけます。

ドライパウダー吸入器（DPI）の開発と改良のために割り当てられた資金は、呼吸器ケアを強化し、効果的な治療法へのアクセスを増やすために不可欠です。例えば、2023年10月、米国食品医薬品局（FDA）はオーストラリアの研究者に100万豪ドル（68万7,000米ドル）の資金を提供し、改善されたドライパウダー吸入器の試験方法を開発しました。このイニシアチブにより、吸入器、特にジェネリック吸入器デバイスのより効果的な開発が可能になり、世界中の喘息患者に手頃な価格の吸入器を提供することを目標としています。

ドライパウダー吸入器の使用に伴う副作用

ドライパウダー吸入器の使用に関連する副作用などの要因は、世界のドライパウダー吸入器市場の妨げになると予想されます。主な問題の1つは口腔鵞口瘡の蔓延であり、これは粉末薬剤が口や喉に定着することで発症する可能性のある真菌症です。調査によると、DPIによる吸入コルチコステロイドの使用は、特に大量投与時に口腔鵞口瘡の発生率を増加させます。患者は、口腔内の不快感、喉の炎症、嗄声などの症状に耐えることがあり、DPIの使用を継続する意欲に影響を与えることがあります。さらに、多くのDPIに頻繁に含まれる乳糖に過敏な人もおり、乳糖不耐症の患者では胃腸の不快感やアレルギー反応を引き起こすことがあります。

局所的な副作用に加えて、DPIによるコルチコステロイドの持続投与による全身的な副作用も懸念されます。長期にわたる高用量投与は、骨粗鬆症、糖尿病、その他の全身疾患などの問題を引き起こす可能性があります。このような潜在的な健康被害は、DPIの長期使用に対する患者の不安を増大させ、処方された治療の不遵守につながる可能性があります。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

• 影響要因
  • 促進要因
  • ドライパウダー吸入器の需要増加
  • 抑制要因
  • ドライパウダー吸入器の使用に伴う副作用
  • 機会
  • 影響分析

第5章 産業分析

• ポーターのファイブフォース分析
• サプライチェーン分析
• 価格分析
• 規制分析
• 償還分析
• 特許分析
• SWOT分析
• DMIの見解

第6章 製品タイプ別

• カプセルベースのデバイス
• ブリスターベースのデバイス
• リザーバー / カートリッジベースのデバイス
• その他

第7章 投与量別

• 単回投与ドライパウダー吸入器
• 多用量ドライパウダー吸入器

第8章 適応症の種類別

• 気管支炎
• 慢性閉塞性肺疾患
• 喘息
• その他

第9章 流通チャネル別

• 病院薬局
• 小売薬局
• オンライン薬局

第10章 地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • イタリア
  • スペイン
  • その他欧州地域
• 南米
  • ブラジル
  • アルゼンチン
  • その他南米
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• 中東・アフリカ

第11章 競合情勢

• 競合シナリオ
• 市況・シェア分析
• M&A分析

第12章 企業プロファイル

• AstraZeneca
  • 会社概要
  • 製品ポートフォリオと概要
  • 財務概要
  • 主な発展
• Boehringer Ingelheim International GmbH
• Vectura Group Ltd
• Otsuka Pharmaceutical Co., Ltd.
• Respira Therapeutics Inc.
• CHIESI Farmaceutici S.p.A.
• Cipla
• GlaxoSmithKline plc.
• Hovione
• Mankind Pharma

第13章 付録

The global dry powder inhalers market reached US$ 1.02 billion in 2024 and is expected to reach US$ 1.56 billion by 2033, growing at a CAGR of 5.1% during the forecast period 2025-2033.

Dry powder inhalers (DPIs) are medical devices that administer powdered drugs directly into the lungs. They are generally used to treat respiratory disorders like asthma and chronic obstructive pulmonary disease (COPD). A dry powder inhaler is distinguished by its breath-activated mechanism, which ensures that the drug is only released when the patient inhales deeply and forcefully via the mouthpiece. Unlike metered-dose inhalers (MDIs), which utilize propellants to administer medication, DPIs employ the patient's inhalation to disperse the powdered medication into an aerosol form that can reach the narrow airways of the lungs.

The increasing demand for dry powder inhalers is the driving factor that drives the market over the forecast period. For instance, the increasing prevalence of respiratory diseases increases the demand for dry powder inhalers since they play a vital role in the treatment and management of chronic respiratory diseases. For instance, according to the Asthma and Allergy Foundation of America, Nearly 28 million people in the United States suffer from asthma. This equates to around one in every twelve people. Asthma affects almost 23 million persons in the United States, aged 18 and older. Asthma is more frequent in women than men. Asthma affects around 11.0% of female adults and 6.8% of male people. It is a major chronic disease among youngsters. Currently, around 4.9 million children under the age of 18 have asthma.

Market Dynamics: Drivers & Restraints

Increasing demand for dry powder inhalers

The increasing demand for dry powder inhalers is expected to be a significant factor in the growth of the global dry powder inhalers market. The increasing number of cases of respiratory disorders, ease of drug delivery than traditional inhalers, technological advancements, increased research funds, and increasing awareness increase the demand for dry powder inhalers and drive the market.

As chronic respiratory conditions like COPD, asthma, and sinusitis become more prevalent globally, the demand for dry powder inhalers increases as it plays an important role in the management and control of chronic respiratory diseases like bronchitis, COPD, and asthma. For instance, according to the Department of Health & Human Services, 1 in 20 people globally suffers from chronic respiratory disease (CRD). East Asia and South Asia had the highest rates of CRD mortality. Low-middle and low Socio-demographic Index (SDI) countries had the highest age-standardized rates of CRD deaths. New findings on chronic respiratory disease (CRD) now show it is the third leading cause of death globally, accounting for approximately 4 million deaths worldwide. Asthma was diagnosed in approximately 60% of these people (approximately 262 million), making it the most common CRD. Since 1990, the number of new cases of CRDs has increased by 49.0%, owing primarily to population growth. The age-standardized incidence rate, on the other hand, has decreased by 5.3%.

The ease of drug delivery and user-friendly nature of dry powder inhalers to traditional inhalers increase the demand. One of the primary advantages of DPIs over typical inhalation devices is their ability to deliver medication directly to the lungs, eliminating the need for propellants or liquids. This attribute not only improves patient compliance but also reduces environmental effects. DPIs are intended to be user-friendly and portable, making them a suitable option for patients who require ongoing treatment for chronic respiratory disorders. The ease and effectiveness of DPIs are projected to drive their acceptance among both healthcare professionals and patients.

Furthermore, technological advancements in DPI design and formulation are driving market expansion. Innovations like capsule-based devices that decrease moisture exposure improve dependability and performance, resulting in higher patient satisfaction and adherence. The incorporation of smart technology into inhalers, such as sensors that monitor usage, creates new prospects for improving treatment outcomes and patient participation. These advancements not only meet existing patient needs but also attract new users who may have previously been unwilling to adopt inhalation therapy.

The funding allocated for the development and improvement of dry powder inhalers (DPIs) is critical to enhancing respiratory care and increasing access to effective therapies. For instance, in October 2023, The US Food and Drug Administration (FDA) funded Australian researchers $AU1 million ($US687,000) to develop improved dry powder inhaler testing procedures. The initiative will enable more effective development of inhalers, particularly generic inhaler devices, with the goal of providing access to affordable inhalers for asthma patients across the globe.

Side effects associated with the usage of dry powder inhalers

Factors such as side effects associated with the usage of dry powder inhalers are expected to hamper the global dry powder inhalers market. One major issue is the prevalence of oral thrush, a fungal disease that can develop when powdered drugs settle in the mouth or throat. According to research, using inhaled corticosteroids via DPIs increases the incidence of oral thrush, especially at larger doses. Patients may endure symptoms such as discomfort in the mouth, throat irritation, and hoarseness, which can influence their willingness to continue using these devices. Furthermore, some people may be sensitive to lactose, a frequent carrier found in many DPIs, which can cause gastrointestinal discomfort or allergic responses in lactose-intolerant patients.

In addition to local side effects, there are concerns regarding systemic side effects from continuous corticosteroid administration via DPIs. High doses over time might result in problems such as osteoporosis, diabetes, and other systemic disorders. These potential health hazards can increase patient anxiety over long-term DPI use and lead to nonadherence to prescribed therapy.

Segment Analysis

The global dry powder inhalers market is segmented based on product type, dosage, indication type, distribution channel, and region.

The multi-dose dry powder inhalers segment is anticipated to dominate the global dry powder inhalers market owing to its cost-effectiveness, longer shelf life, ease of use, strategic partnerships, and increasing prevalence of respiratory disorders.

One of the primary benefits of MDPIs is their cost-effectiveness. These devices often have a longer shelf life and less pharmaceutical waste, making them cost-effective for both patients and healthcare systems. The combination of price and ease of use makes MDPIs a popular alternative, particularly as healthcare providers prioritize effective and efficient respiratory disease treatment solutions.

Technological developments will also play an important part in the expansion of the multi-dose segment. Smart inhalers, which combine digital health solutions, improve patient involvement and treatment adherence. These devices can monitor usage patterns, remind patients to take their prescriptions and provide feedback on inhaling practices, ultimately enhancing treatment outcomes. As healthcare systems increasingly adopt digital health technology, MDPIs are likely to gain from greater integration into patient care initiatives.

For instance, according to the American Lung Association, COPD affects 11.7 million adults, resulting in hundreds of thousands of emergency department visits and tens of billions of dollars in healthcare expenses each year. Moreover, according to the Cystic Fibrosis Foundation, Cystic fibrosis affects about 40,000 children and adults in the United States (an estimated 105,000 people have been diagnosed with the disease in 94 countries), and it can affect people of any ethnic background. So, multi-dose dry powder inhalers play an important role in the treatment and management of chronic respiratory disorders. The increasing number of chronic respiratory disorders upsurges the demand for multi-dose dry powder inhalers.

The strategic partnerships took place to enhance the quality and efficiency of the multi-dose dry powder inhalers. For instance, in May 2023, H&T Presspart, a global supplier of drug delivery devices and components, announced a collaborative partnership with Hovione, a specialist integrated CDMO and leader in spray drying and particle engineering, to develop the new Sunrise high-performance dry powder inhaler technology platform. H&T Presspart's revolutionary Sunriser technology is adaptable enough to meet the challenges of both traditional carrier-based and spray-dried tailored formulations, as well as an expanding range of dry powder formulations, new particle engineering, and powder processing technologies. As part of the collaborative development agreement, H&T Presspart will continue to develop and manufacture the Sunriser device.

Geographical Analysis

The dominance of the North American market in the global dry powder inhaler market is due to various factors such as advanced healthcare infrastructure, high prevalence of respiratory diseases, strategic partnerships, technological advancements, product launches, and approvals, and increasing adoption of innovative medical technologies.

One of the primary factors contributing to North America's dominance in the dry powder inhaler market is technological improvements that improve the functionality and user experience of dry powder inhalers. Recent advances have focused on enhancing device usability, drug delivery accuracy, and patient adherence. Many recent DPI advancements include integrated dose counters and audible feedback mechanisms that assist patients in receiving the exact dosage while also serving as medication adherence reminders. Furthermore, advances in materials and design have resulted in the creation of lightweight, portable inhalers that are easier for patients to transport and use on the go.

For instance, in February 2024, Catalent, Inc., a global leader in enabling the development and supply of better therapies for patients, completed remodeling and device advancement to its capsule filling of Dry Powders for Inhalation and capsule blistering suites in Boston, MA, to handle strong pharmaceuticals. Catalent is currently the CDMO with the most GMP capacity for capsule spray-dried and carrier-based inhaled powders, due to recent enhancements that include more capacity for both development and commercial spray drying.

The increasing prevalence of respiratory disorders in this region increases the demand for dry powder inhalers. For instance, according to health.gov, respiratory diseases affect millions of people in the United States. More than 25 million people in the United States have asthma. Strategies to reduce environmental triggers and make sure people get the right medications can help prevent hospital visits for asthma. In addition, more than 16 million people in the United States have COPD (chronic obstructive pulmonary disease), which is a major cause of death.

Asia Pacific is growing at the fastest pace in the global dry powder inhalers market

The Asia Pacific region is emerging as the fastest-growing market for dry powder inhalers, owing to a combination of demographic trends, increased healthcare investment, recent launches, and an increasing prevalence of respiratory diseases.

The increasing prevalence of respiratory diseases is one of the factors that drive the market in this region. For instance, according to The International Primary Care Respiratory Group, India has one of the highest rates of chronic respiratory illness. India accounts for 15.69% of worldwide chronic respiratory diseases, whereas 30.28% of all global deaths from chronic respiratory diseases occur in India. India has the world's greatest number of COPD (Chronic Obstructive Pulmonary Disease) cases, totaling 55.23 million. India has the second-highest number of COPD-related deaths globally, accounting for almost 0.85 million.

There are recent product launches of anesthesia devices in this region. For instance, in 2023, Aptar Pharma launched Orbital Dry Powder Inhaler (DPI), a revolutionary device for delivering high-payload powder medication formulations directly to the lungs. This innovative inhaler technology stands out for its ability to give accurate and consistent dosing over several inhalations, which improves patient compliance and minimizes the risk of coughing during administration. The Orbital DPI is adaptable to both single-use and reuse applications, making it suitable for a wide range of therapeutic purposes.

Competitive Landscape

The major global players in the global dry powder inhalers market include AstraZeneca, Boehringer Ingelheim International GmbH, Vectura Group Ltd, Otsuka Pharmaceutical Co., Ltd., Respira Therapeutics Inc., CHIESI Farmaceutici S.p.A., Cipla, GlaxoSmithKline plc., Hovione, Mankind Pharma among others.

Emerging Players

Merxin Ltd, Aerovate Therapeutics, and PULMATRiX, Inc. among others

Key Developments

• In November 2024, Aptar Pharma, a global leader in drug delivery and active material science solutions and services, announced that it has signed an exclusive collaboration agreement with Cambridge Healthcare Innovations (CHI) to commercialize and promote its Quattrii Dry Powder Inhaler (DPI) platform.
• In April 2024, Berry Global, a leader in the design, development, and manufacturing of patient-centered healthcare solutions, recently introduced the BerryHaler, a dual chamber, dry powder inhaler (DPI) with a dose counter that improves patient access to and supports the effective delivery of combination drugs.

Why Purchase the Report?

• Pipeline & Innovations: Reviews ongoing clinical trials, product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
• Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
• Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
• Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
• Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
• Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
• Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
• Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
• Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
• Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
• Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
• Post-market Surveillance: Uses post-market data to enhance product safety and access.
• Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global dry powder inhalers market report delivers a detailed analysis with 60+ key tables, more than 50 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2024

• Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
• Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
• Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
• Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
• Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
• Supply Chain: Distribution and Supply Chain Managers.
• Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
• Academic & Research: Academic Institutions.

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Product Type
• 3.2. Snippet by Dosage
• 3.3. Snippet by Indication Type
• 3.4. Snippet by Distribution Channel
• 3.5. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
  • 4.1.2. Increasing Demand for Dry Powder Inhalers
  • 4.1.3. Restraints
  • 4.1.4. Side Effects Associated with The Usage of Dry Powder Inhalers
  • 4.1.5. Opportunity
  • 4.1.6. Impact Analysis

5. Industry Analysis

• 5.1. Porter's Five Force Analysis
• 5.2. Supply Chain Analysis
• 5.3. Pricing Analysis
• 5.4. Regulatory Analysis
• 5.5. Reimbursement Analysis
• 5.6. Patent Analysis
• 5.7. SWOT Analysis
• 5.8. DMI Opinion

6. By Product Type

• 6.1. Introduction
  • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 6.1.2. Market Attractiveness Index, By Product Type
• 6.2. Capsule Based Device*
  • 6.2.1. Introduction
  • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 6.3. Blister Based Devices
• 6.4. Reservoir/Cartridge Based Devices
• 6.5. Others

7. By Dosage

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Dosage
  • 7.1.2. Market Attractiveness Index, By Dosage
• 7.2. Single-Dose Dry Powder Inhalers*
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 7.3. Multi-Dose Dry Powder Inhalers

8. By Indication Type

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication Type
  • 8.1.2. Market Attractiveness Index, By Indication Type
• 8.2. Bronchitis*
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 8.3. COPD
• 8.4. Asthma
• 8.5. Others

9. By Distribution Channel

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 9.1.2. Market Attractiveness Index, By Distribution Channel
• 9.2. Hospital Pharmacies*
  • 9.2.1. Introduction
  • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 9.3. Retail Pharmacies
• 9.4. Online Pharmacies

10. By Region

• 10.1. Introduction
  • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 10.1.2. Market Attractiveness Index, By Region
• 10.2. North America
  • 10.2.1. Introduction
  • 10.2.2. Key Region-Specific Dynamics
  • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Dosage
  • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication Type
  • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 10.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.2.7.1. The U.S.
    • 10.2.7.2. Canada
    • 10.2.7.3. Mexico
• 10.3. Europe
  • 10.3.1. Introduction
  • 10.3.2. Key Region-Specific Dynamics
  • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Dosage
  • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication Type
  • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 10.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.3.7.1. Germany
    • 10.3.7.2. UK
    • 10.3.7.3. France
    • 10.3.7.4. Italy
    • 10.3.7.5. Spain
    • 10.3.7.6. Rest of Europe
• 10.4. South America
  • 10.4.1. Introduction
  • 10.4.2. Key Region-Specific Dynamics
  • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Dosage
  • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication Type
  • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 10.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.4.7.1. Brazil
    • 10.4.7.2. Argentina
    • 10.4.7.3. Rest of South America
• 10.5. Asia-Pacific
  • 10.5.1. Introduction
  • 10.5.2. Key Region-Specific Dynamics
  • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Dosage
  • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication Type
  • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 10.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.5.7.1. China
    • 10.5.7.2. India
    • 10.5.7.3. Japan
    • 10.5.7.4. South Korea
    • 10.5.7.5. Rest of Asia-Pacific
• 10.6. Middle East and Africa
  • 10.6.1. Introduction
  • 10.6.2. Key Region-Specific Dynamics
  • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Dosage
  • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication Type
  • 10.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

11. Competitive Landscape

• 11.1. Competitive Scenario
• 11.2. Market Positioning/Share Analysis
• 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

• 12.1. AstraZeneca *
  • 12.1.1. Company Overview
  • 12.1.2. Product Portfolio and Description
  • 12.1.3. Financial Overview
  • 12.1.4. Key Developments
• 12.2. Boehringer Ingelheim International GmbH
• 12.3. Vectura Group Ltd
• 12.4. Otsuka Pharmaceutical Co., Ltd.
• 12.5. Respira Therapeutics Inc.
• 12.6. CHIESI Farmaceutici S.p.A.
• 12.7. Cipla
• 12.8. GlaxoSmithKline plc.
• 12.9. Hovione
• 12.10. Mankind Pharma

LIST NOT EXHAUSTIVE

13. Appendix

• 13.1. About Us and Services
• 13.2. Contact Us